Shield Therapeutics Gestione
Gestione criteri di controllo 3/4
Shield Therapeutics Il CEO è Anders Lundstrom, nominato in Jul2024, ha un mandato di meno di un anno. possiede direttamente 0.001% delle azioni della società, per un valore di £ 285.29. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.6 anni e 4 anni.
Informazioni chiave
Anders Lundstrom
Amministratore delegato
US$53.5k
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | less than a year |
| Proprietà del CEO | 0.001% |
| Durata media del management | 1.6yrs |
| Durata media del Consiglio di amministrazione | 4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15AMMINISTRATORE DELEGATO
Anders Lundstrom (62 yo)
less than a year
Mandato
US$53,542
Compensazione
Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | less than a year | US$53.54k | 0.0013% £ 285.3 | |
| Co-Founder & Non Executive Director | 16.8yrs | US$47.17k | 1.49% £ 332.1k | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| General Counsel & Company Secretary | 7.2yrs | Nessun dato | Nessun dato | |
| Group HR Director | no data | Nessun dato | Nessun dato | |
| Head of Pharmacovigilance & Medical Information | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Senior Director of People & Culture | no data | Nessun dato | Nessun dato |
1.6yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di STX non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | 3.5yrs | US$53.54k | 0.0013% £ 285.3 | |
| Co-Founder & Non Executive Director | 4.4yrs | US$47.17k | 1.49% £ 332.1k | |
| Independent Non Executive Chairman | 6.3yrs | US$119.83k | 0.70% £ 156.7k | |
| Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 8.8yrs | US$76.49k | 0.023% £ 5.1k | |
| Notable Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 3.5yrs | US$47.17k | 0.035% £ 7.7k | |
| Notable Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Notable Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Notable Scientific Advisory Board | no data | Nessun dato | Nessun dato |
4.0yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di STX sono considerati esperti (durata media dell'incarico 4 anni).